Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
This security has been delisted
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Search results

Roche Holding AG ADR

WKN: 891106 / Symbol: RHHBY / Name: Roche / Stock / Pharmaceuticals / Large Cap /

€45.13
0.510%

6 3
6
3
Roche Bobois S.a.

WKN: A2JQRU / Name: Roche Bobois S.a. / Stock / ? /

€19.95
-2.210%

0 0
0
0
Roche Holding AG

WKN: A4124Y / Name: Roche Holding / Stock / ? /

€16.30
0.000%

1 0
1
0
Roche Holding AG

WKN: A40CGQ / Name: Roche Holding / Stock / ? /

€7.60
0.660%

0 0
0
0
Roche Finance Europe B.v.

WKN: A3LEL7 / Name: Roche Finance Europe B.v. / Stock / ? /

€102.31
0.070%

0 0
0
0
Roche Finance Europe B.v.

WKN: A3LEL8 / Name: Roche Finance Europe B.v. / Stock / ? /

€101.78
0.070%

0 0
0
0
Roche Finance Europe B.v.

WKN: A3LRTS / Name: Roche Finance Europe B.v. / Stock / ? /

€101.67
0.000%

0 0
0
0
Roche Finance Europe B.v.

WKN: A3LRTT / Name: Roche Finance Europe B.v. / Stock / ? /

€101.66
0.160%

0 0
0
0
Roche Finance Europe B.v.

WKN: A3LX6K / Name: Roche Finance Europe B.v. / Stock / ? /

€102.62
0.030%

0 0
0
0
Roche Finance Europe B.v.

WKN: A3LX6L / Name: Roche Finance Europe B.v. / Stock / ? /

€95.64
0.160%

0 0
0
0
Roche Holdings Inc.

WKN: A3LVX8 / Name: Roche Holdings Inc. / Stock / ? /

€97.84
0.510%

0 0
0
0
Roche Holding AG

WKN: A424UK / Name: Roche Holding / Stock / ? /

€358.84
-0.710%

2 0
2
0
Roche Aktie: cobas HDV-Test gestartet
Roche Aktie: cobas HDV-Test gestartet

Hepatitis D gilt als die gefährlichste Form der viralen Leberentzündung. Sie trifft nur Menschen,…

Der Beitrag Roche Aktie: cobas HDV-Test gestartet erschien zuerst auf kapitalmarktexperten.de.

Quel

TorstenPinkert 
0 14.07.26
Rochefocauld
Account activated

21.01.21
RHHBY's Gazyva Gets FDA Priority Review for Label Expansion
RHHBY's Gazyva Gets FDA Priority Review for Label Expansion

Roche RHHBY announced that the FDA has granted Priority Review to the company’s supplemental biologics license application (sBLA) seeking label expansion of Gazyva/Gazyvaro (obinutuzumab).

The sBLA

Zacks 
0 15.07.26